Role of Hepcidin as a biomarker for iron status in patients on regular hemodialysis

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Magdy M. El Sharkawy ◽  
Mohamed Saeed Hassan ◽  
Lina Essam Khedr ◽  
Marco Monir Hanna
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Iron Status ◽  
Ferritin Level ◽  
Current Evidence ◽  
Iron Level ◽  
Iron Release ◽  
Hepcidin Level ◽  
Stage Renal Disease ◽  
End Stage

Abstract Background The etiology of anemia in End Stage Renal Disease is multifactorial. Importantly, ESRD patients also have several abnormalities in systemic homeostasis of iron, an essential component in the production of red blood cells. Aim of the Work to assess hepcidin level in negative virology End Stage Renal Disease patients & its relation to iron level and erythropoiesis. Patients and Methods This study was conducted on 45 patients who are stage V chronic kidney disease on regular haemodialysis. Ten age and sex matched controls were included in the study. The study included 29 (64.4%) males and 16 (35.6%) females; their mean age was 53.40± 11.56 years. The prevalence of diabetes among the studied cases was 17.8%, while that of hypertensive was 42.2%. Mean of serum iron level was 64.23±19.53. Mean of TIBC was 409.96±67.85. Mean of Ferritin level 394.55±139.23 and mean of Hepcidin level was 218.51±127. Results Significant negative correlation between Hepcidin level and the Hemoglobin level, and highly significant positive correlation between Hepcidin level and serum Ferritin. Hepcidin up-regulation in the setting of CKD, with subsequent increased serum levels, results in impaired iron absorption from the intestine and decreased iron release from body storage sites. Ultimately, in the setting of such elevated levels, a state of functional iron deficiency may develop and lead to anemia due to iron-restricted erythropoiesis. Conclusion Based on current evidence, it seems likely that hepcidin represents a potentially modifiable mediator of anemia of CKD and is thus a potential target for future anemia therapy.

scholarly journals Associations of Common Variants in HFE and TMPRSS6 Genes with Hepcidin-25 and Iron Status Parameters in Patients with End-Stage Renal Disease

2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
Violeta Dopsaj ◽  
Aleksandra Topić ◽  
Miljan Savković ◽  
Neda Milinković ◽  
Ivana Novaković ◽  
...  
Keyword(s):  
Renal Disease ◽  
Diagnostic Accuracy ◽  
End Stage Renal Disease ◽  
Iron Status ◽  
Transferrin Saturation ◽  
Deficiency Anemia ◽  
Control Group ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background. Influence of TMPRSS6 A736V and HFE (C282Y and H63D) polymorphisms on serum hepcidin-25 levels and iron status parameters in end-stage renal disease (ESRD) patients stratified according to gender has not been previously investigated. In addition, we aimed to evaluate the diagnostic accuracy of the parameters to separate iron-deficiency anemia (IDA) from anemia of chronic disease. Materials and Methods. Iron status parameters and genetic analysis were performed in 126 ESRD patients and in 31 IDA patients as the control group. Results. ESRD patients had significantly higher ferritin and hepcidin-25 (<0.001) relative to IDA patients. Cut-off values with the best diagnostic accuracy were found for hepcidin ≥9.32 ng/mL, ferritin ≥48.2 μg/L, transferrin saturation ≥16.8%, and MCV ≥81 fL. Interaction between gender and HFE haplotypes for the hepcidin-25 and ferritin levels in ESRD patients (p=0.005, partial eta squared=0.09; p=0.027, partial eta squared=0.06, respectively) was found. Serum transferrin was influenced by the combined effect of gender and TMPRSS6 A736V polymorphism in ESRD patients (p=0.002, partial eta squared=0.07). Conclusion. Our findings could contribute to the further investigation of mechanisms involved in the pathophysiology and important gender-related involvement of the TMPRSS6 and HFE polymorphisms on anemia in ESRD patients.

scholarly journals The Growth Attainment, Hematological, Iron Status and Inflammatory Profile of Guatemalan Juvenile End-Stage Renal Disease Patients

PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0140062 ◽  
Author(s):  
Juliana Casimiro de Almeida ◽  
Randall Lou-Meda ◽  
Marion Olbert ◽  
Markus Seifert ◽  
Günter Weiss ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Iron Status ◽  
Inflammatory Profile ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals The relation between vitamin D status and anemia in patients with end stage renal disease on regular hemodialysis

2021 ◽  
Vol 7 (1) ◽  
pp. e15-e15
Author(s):  
Essam Nour el Din Afifi ◽  
Ahmed Mohamed Tawfik ◽  
Essam Eldin Rashed Saeed Abdulkhalek ◽  
Lina Essam Khedr
Keyword(s):  
Vitamin D ◽  
Renal Disease ◽  
Serum Calcium ◽  
End Stage Renal Disease ◽  
Iron Status ◽  
Vitamin D Status ◽  
Vitamin D Levels ◽  
Stage Renal Disease ◽  
End Stage ◽  
Regular Hemodialysis

Introduction: Anemia is a common complication in end-stage renal disease (ESRD) patients on regular hemodialysis (HD). There has been a lot of interest recently in the non-classical effects of 25(OH) vitamin D (calcidiol), including its association with erythropoiesis and anemia pathogenesis. Objectives: To study the relation between anemia and vitamin D status in patients on regular HD Results: This study is a cross-sectional study that included 90 patients on regular HD. Vitamin D status was classified into deficient (<20 ng/ mL), insufficient (20-30 ng/mL) and sufficient (>30 ng/mL). The level of vitamin D measured in the patients ranged between 3.5 to 66 ng/mL with median of 16.35 ng/mL. There were statistically significant positive correlations between vitamin D levels and the level of hemoglobin (P<0.001), serum calcium levels (P<0.001) and serum PO4 levels (P=0.023). Higher hemoglobin levels were statistically related to both higher vitamin D values (P<0.001) and higher serum calcium concentration P<0.001). Meanwhile, a significant negative correlation was found between hemoglobin levels and serum PTH values (P<0.001). Conclusion: There was a significant association between the status of vitamin D and the level of hemoglobin in dialysis population who were studied, independent from iron status. other associations with hemoglobin levels included PTH level and calcium.

scholarly journals Low-Dose Maintenance Intravenous Iron Therapy Can Prevent Anemia in Children with End-Stage Renal Disease Undergoing Chronic Hemodialysis

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Cahyani Gita Ambarsari ◽  
Partini Pudjiastuti Trihono ◽  
Agustina Kadaristiana ◽  
Dedi Rachmadi ◽  
Murti Andriastuti ◽  
...  
Keyword(s):  
Treatment Group ◽  
Renal Disease ◽  
Maintenance Therapy ◽  
End Stage Renal Disease ◽  
Comparison Group ◽  
Iron Status ◽  
Iv Iron ◽  
Stage Renal Disease ◽  
End Stage ◽  
Regular Hemodialysis

Iron deficiency anemia is common in children with end-stage renal disease (ESRD) on long-term hemodialysis receiving erythropoiesis-stimulating agents. One approach to maintain the iron profile and hemoglobin levels is maintenance therapy with regular low doses of intravenous (IV) iron after initial iron repletion therapy; however, evidence for the benefits of this approach is lacking. This study evaluated the effect of IV iron maintenance therapy on anemia in children on regular hemodialysis. This retrospective cohort study included 41 pediatric ESRD patients with normal hemoglobin and iron status who underwent regular hemodialysis at the Pediatric Dialysis Unit of Cipto Mangunkusumo Hospital, Indonesia, between January 2015 and April 2019. Among these, 21 received IV iron maintenance therapy with two doses of 2 mg/kg of IV iron sucrose every 2 weeks (the treatment group) and 20 did not (the comparison group). Changes in hemoglobin and transferrin saturation were assessed after 6 weeks of observation and compared between the two groups. There was a significant reduction in the mean hemoglobin level compared with the baseline level in the comparison group (21 g/L; 95% CI, 9.3–33 g/L; p=0.001) but not in the treatment group (0.7 g/L; 95% CI, −6.6–8 g/L; p=0.84). The risk of anemia was lower in the treatment group (relative risk = 0.42; 95% CI, 0.22–0.79; p=0.003). Although majority of the patients had high baseline ferritin level, this study indicates that in our setting, ferritin may not be a reliable parameter to review the iron status, as it can be affected by chronic inflammation. Hence, the decision to start IV iron maintenance therapy in patients with hyperferritinemia should consider the patient’s clinical condition and morbidity. To conclude, the coadministration of IV iron maintenance therapy is beneficial for maintaining hemoglobin levels and preventing anemia in children with ESRD who are undergoing regular hemodialysis, have achieved the target hemoglobin levels, and have normal iron status.

scholarly journals Gambaran kadar feritin pada pasien penyakit ginjal kronik stadium 5 non dialisis

2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Teresita Puspitaningrum ◽  
Glady I. Rambert ◽  
Mayer F. Wowor
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Ferritin Level ◽  
Normocytic Anemia ◽  
Iron Storage ◽  
Consecutive Sampling ◽  
Stage Renal Disease ◽  
End Stage

Abstract: Ferritin is a major iron storage protein in human tissues. It functions as an iron storage especially in liver, spleen, and bone marrow. Anemia occurs in 80-90% chronic kidney disease (CKD) patients; the most common type of anemia is normocytic anemia. WHO assumes that in Indonesia chronic kidney disease patients will increase 41.4% in 1995-2025. This study aimed to obtaind ferritin level in non dialysis end-stage renal disease patients. This was a descriptive study with a cross sectional design. Data of ferritin levels in non dialysis end-stage renal disease patients were obtained from two hospitals, Prof. Dr. R. D. Kandou Hospital Manado and Advent Hospital Manado, from December 2015 to January 2016. Blood samples of 35 patients suffering from non dialysis end-stage renal disease were obtained by using non-probability consecutive sampling method. The results showed that of the 35 patients, there were 28 patients with increased ferritin levels and 7 patients with normal ferritin level. Conclusion: Increased ferritin level occurred among non dialysis end-stage renal disease patients.Keywords: ferritin level, non-dialysis end-stage renal disease. Abstrak: Feritin adalah protein penyimpan zat besi utama yang ditemukan pada jaringan tubuh manusia. Fungsi feritin ialah sebagai penyimpanan zat besi terutama di dalam hati, limpa, dan sumsum tulang. Anemia terjadi pada 80-90% pasien penyakit ginjal kronik (PGK) dengan jenis normositik yang paling umum ditemukan. WHO memperkirakan di Indonesia akan terjadi peningkatan penderita gagal ginjal pada tahun 1995-2025 sebesar 41,4%. Penelitian ini bertujuan untuk mengetahui gambaran kadar feritin pada PGKstadium 5 non dialisis. Jenis penelitian ini ialah deskriptif dengan desain potong lintang. Data kadar feritin pada pasien PGK stadium 5 non dialisis diperoleh dari dua rumah sakit yaitu RSUP Prof. Dr. R. D. Kandou Manado dan Rumah Sakit Advent Manado sejak Desember 2015-Januari 2016. Sampel darah dari 35 pasien PGK ditentukan dengan cara non-probability consecutive sampling. Hasil penelitian memperlihatkan dari 35 pasien yang terdiagnosis PGK stadium 5 non dialisis terdapat 28 pasien dengan peningkatan kadar ferritin dan 7 pasien dengan kadar ferritin normal. Simpulan: Peningkatan kadar feritin dapat terjadi pada pasien penyakit ginjal kronik stadium 5 non dialisis. Kata kunci: kadar feritin, penyakit ginjal kronik stadium 5 non dialisis

scholarly journals Status of Selected Iron‐Status Biomarkers in Juvenile End‐ Stage Renal Disease in a Guatemalan Context: Comparative Aspects by Mode of Dialysis

2013 ◽  
Vol 27 (S1) ◽  
Author(s):  
Juliana Casimiro ◽  
Randall Lou‐Meda ◽  
Marion Olbert ◽  
Günter Weiss ◽  
Dorine W Swinkels ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Iron Status ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document